Moderna swings to profit as momentum for cancer vaccine builds - Financial Times — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Moderna reported third-quarter 2026 financial results and business updates, swinging to profit as momentum builds around its cancer vaccine.
- Moderna boosted revenue guidance on the strength of its COVID vaccine, and its stock jumped after the biotech raised its sales outlook.
Why it matters: Moderna's third-quarter 2026 report matters twice: the company swung to profit and raised its sales outlook, sending the stock higher, while momentum builds around its cancer vaccine. Shareholders are getting a stronger COVID franchise today alongside a pipeline that carries the longer-run argument.
Ask SkimNews
